Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Rubin

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
The New England Journal of Medicine|January 17, 2003
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancerLin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, et al.
Gynecologic Oncology|August 9, 2011
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group studyDon S Dizon, Michael W Sill, Natalie Gould, et al.
Gynecologic Oncology|February 1, 2011
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group studyMark A Morgan, Michael W Sill, Keiichi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control studyAngela DeMichele, Andrea B Troxel, Jesse A Berlin, et al.
Cancer Immunology, Immunotherapy : CII|October 25, 2011
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remissionChristina S Chu, Jean Boyer, Daniel S Schullery, et al.
Journal of the National Cancer Institute|September 21, 2006
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer riskTimothy R Rebbeck, Andrea B Troxel, Yiting Wang, et al.
Gynecologic Oncology|March 19, 2018
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group studyRamez N Eskander, James Kauderer, Krishnansu S Tewari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosisStephen M Hahn, Douglas L Fraker, Rosemarie Mick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patientsKatia Schlienger, Christina S Chu, Edward Y Woo, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The New England Journal of Medicine|January 17, 2003
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancerLin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, et al.
Gynecologic Oncology|August 9, 2011
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group studyDon S Dizon, Michael W Sill, Natalie Gould, et al.
Gynecologic Oncology|February 1, 2011
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group studyMark A Morgan, Michael W Sill, Keiichi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control studyAngela DeMichele, Andrea B Troxel, Jesse A Berlin, et al.
Cancer Immunology, Immunotherapy : CII|October 25, 2011
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remissionChristina S Chu, Jean Boyer, Daniel S Schullery, et al.
Journal of the National Cancer Institute|September 21, 2006
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer riskTimothy R Rebbeck, Andrea B Troxel, Yiting Wang, et al.
Gynecologic Oncology|March 19, 2018
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group studyRamez N Eskander, James Kauderer, Krishnansu S Tewari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2006
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosisStephen M Hahn, Douglas L Fraker, Rosemarie Mick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group StudyRobert A Burger, Mark F Brady, Michael A Bookman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patientsKatia Schlienger, Christina S Chu, Edward Y Woo, et al.
Pageof 6